Title :

Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.

Author(s) :

Swan, D. [Auteur]
Hayden, P. J. [Auteur]
Eikema, D. J. [Auteur]
Koster, L. [Auteur]
Sauer, S. [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Nicholson, E. [Auteur]
Rabin, N. [Auteur]
Touzeau, Cyrille [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Byrne, J. [Auteur]
Huynh, Anne [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Cornelissen, J. J. [Auteur]
Potter, V. [Auteur]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Parrish, C. [Auteur]
Gribben, J. [Auteur]
Chretien, Marie-Lorraine [Auteur]
CHU Dijon
Mielke, S. [Auteur]
Gedde-Dahl, T. [Auteur]
Reményi, P. [Auteur]
Tsirigotis, P. [Auteur]
Garcia Guiñón, A. [Auteur]
Beksac, M. [Auteur]
Schönland, S. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

British Journal of Haematology

Abbreviated title :

Br J Haematol

Volume number :

197

Pages :

82-96

Publication date :

2022-02-17

ISSN :

1365-2141

English keyword(s) :

myeloma
stem cell transplantation
autologous

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Multiple myeloma (MM) accounts for 10% of haematological malignancies. Overall survival (OS) has improved in recent years due to increased use of autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed ...
Show more >Multiple myeloma (MM) accounts for 10% of haematological malignancies. Overall survival (OS) has improved in recent years due to increased use of autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed MM and the advent of novel agents, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. To assess trends in ASCT including patient selection, choice of induction regimen, depth of response and survival, we performed a retrospective analysis of all patients undergoing first ASCT for MM in European Society for Blood and Marrow Transplantation centres between 1995 and 2019. A total of 117 711 patients across 575 centres were included. The number of transplants performed increased sevenfold across the study period. The median age increased from 55 to 61 years, and the percentage of patients aged >65 years rose from 7% to 30%. Use of chemotherapy-based induction fell significantly, being largely replaced by bortezomib-based regimens. The two-year complete response rate increased from 22% to 42%. The five-year progression-free survival and OS rates increased from 28% to 31% and from 52% to 69%, respectively. Transplant mortality fell from 5.9% to 1.5%. Ongoing advances in MM treatment may challenge the future role of ASCT. However, at the current time, ASCT remains central to the MM treatment paradigm.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T02:16:40Z
2024-03-22T09:25:55Z